Fact CheckerSign in

NCT06553053Recruiting

Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial

Source: ClinicalTrials.gov · Last updated 13 Apr 2026

Brief summary (registry, in English)

The aim of this study was to further improve the clinical efficacy of acupuncture in delaying the clinical recurrence of CD and to explore the efficacy mechanism of acupuncture efficacy enhancement.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
106 (estimated)
First submitted
7 Aug 2024
Start date
13 Aug 2024
Primary completion date
31 Dec 2028
Lead sponsor
Shanghai Institute of Acupuncture, Moxibustion and Meridian
NCT number
NCT06553053

What you commit to

  • Study type: Interventional
  • Planned participants: 106
  • From 13 Aug 2024 to the primary completion date, 31 Dec 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • patients with serious organic diseases;
  • patients who suffer from multiple diseases and need to take other drugs for a long time, and may affect the observation of the efficacy of this trial;
  • severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious extraintestinal manifestations;
  • there are serious intestinal fistula, abdominal abscess, intestinal stenosis and obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and other complications;
  • patients with short bowel syndrome who have undergone abdominal or gastrointestinal surgery in the past half a year;
  • there are skin diseases or defects in the selected area of acupuncture and moxibustion that cannot be performed.

Other

  • patients who are recently pregnant or in pregnancy or lactation;
  • patients diagnosed as psychosis;

Who the study is looking for

  • patients with clinical diagnosis consistent with CD;
  • aged 16-75;
  • patients in remission (CDAI \< 150 and CRP \< 5mg/l, or Faecal calprotectin \< 50μg/g, or no ulcer under endoscopy);
  • patients with frequent disease recurrences (≥2) in the past years;
  • patients were not taking medication or were only taking one or more of the following drugs: \[mesalazine (≤4g/d), prednisone (≤15mg/d), azathioprine (≤1mg/kg/d)\] and prednisone and mesalazine were used for at least 1 month, while azathioprine was used for at least 3 months; or those who had poor response or loss of response to biological preparations (anti-TNF-α, IL-12p40, α4β7);
  • those who have never experienced acupuncture;
  • patients signing informed consent.

Age in the registry: 16 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Shanghai Research Institute of Acupuncture and Meridian
Coordinator of this site? Confirm its status
ShanghaiChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.